Daiichi Sankyo And Aussie Biotech Biota Begin Phase III Asian Trials For Second-Generation Flu Drug
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Daiichi Sankyo and Australian partner Biota have begun pivotal Phase III trials for anti-influenza drug CS-8958 in Japan, Taiwan, Hong Kong and Korea
You may also be interested in...
Positive Phase III Results For Relenza Follow-On Owned By Aussie Biotech Biota, Japanese Daiichi Sankyo
PERTH, Australia - Australian biotech Biota Holdings announced positive Phase III results of its Asian clinical trials for second-generation influenza treatment CS-8958, co-developed and co-owned with Daiichi Sankyo
Positive Phase III Results For Relenza Follow-On Owned By Aussie Biotech Biota, Japanese Daiichi Sankyo
PERTH, Australia - Australian biotech Biota Holdings announced positive Phase III results of its Asian clinical trials for second-generation influenza treatment CS-8958, co-developed and co-owned with Daiichi Sankyo
Positive Phase III Results For Relenza Follow-On Owned By Aussie Biotech Biota And Daiichi Sankyo
Japanese approval is anticipated in 2010, but Biota is seeking an ex-Japan development partner to replicate Asian studies and seek U.S. and European approvals.